NACC2 Antibody | 58-673

NACC2 Antibody | 58-673 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: This NACC2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 473-502 amino acids from the C-terminal region of human NACC2.

Research Area: Other

Tested Application: WB

Application: For WB starting dilution is: 1:1000

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 63 kDa

Validation: N/A

Isoform: N/A

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Clonality: Polyclonal

Clone: N/A

Isotype: Rabbit Ig

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.

Concentration: batch dependent

Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Nucleus accumbens-associated protein 2, NAC-2, BTB/POZ domain-containing protein 14A, Repressor with BTB domain and BEN domain, NACC2, BTBD14A, NAC2, RBB

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: BTBD14A (BTB/POZ domain-containing protein 14A) , also known as BTBD14, is a 587 amino acid protein that contains one BTB/POZ domain. The BTB/POZ domain mediates homomeric and heteromeric POZ-POZ interactions and is common to transcriptional regulators involved in chromatin modeling. In several BTB/POZ containing proteins, including BCL-6 and the promyelocytic leukemia zinc-finger (PLZF) oncoprotein, this domain interacts with the SMRT/N-CoR-mSin3A HDAC complex and is directly involved in repressing and silencing gene transcription. When this domain is deleted, as with the oncogenic PLZF-RAR chimera of promyelocytic leukemias, this transcriptional repression is attenuated. This suggests that BTBD14A may play a role in transcription regulation.